相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
David S. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial
Ana Oaknin et al.
JAMA ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis
N. A. J. Ryan et al.
GENETICS IN MEDICINE (2019)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
Yoland Catherine Antill et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
1044PPembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study
D O'Malley et al.
ANNALS OF ONCOLOGY (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Global, Regional, and National Burden of Endometrial Cancer, 1990-2017: Results From the Global Burden of Disease Study, 2017
Shuang Zhang et al.
FRONTIERS IN ONCOLOGY (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters
Janelle B. Pakish et al.
CLINICAL CANCER RESEARCH (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Second-Line Therapy for Endometrial Cancer: The Need for Better Options
Gini F. Fleming
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt et al.
JAMA ONCOLOGY (2015)
Endometrial Cancer and Lynch Syndrome: Clinical and Pathologic Considerations
Larissa A. Meyer et al.
CANCER CONTROL (2009)
分享论文
